Conditions: Asthma
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 32
Healthy volunteers: no

Brief summary:
The primary objective of this study is to assess the efficacy (bronchoprotection) and safety of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the Respimat® inhaler, in patients with intermittent asthma.

Detailed description:

Arms:
arm 1: Single dosing of low dose Olodaterol inhaled orally from Respimat Device arm 2: Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device arm 3: Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device arm 4: Single dosing of high dose Olodaterol inhaled orally from Respimat Device arm 5: Single dosing of Olodaterol placebo inhaled orally from Respimat Device

Interventions: intervention 1: Placebo intervention 2: Olodaterol (BI1744CL) intervention 3: Olodaterol (BI1744CL) intervention 4: Olodaterol (BI1744CL) intervention 5: Olodaterol (BI1744CL)
Intervention descriptions: intervention 1: Placebo device for comparison intervention 2: Olodaterol comparison of low, medium low, medium high and high doses intervention 3: Olodaterol comparison of low, medium low, medium high and high doses intervention 4: Olodaterol comparison of low, medium low, medium high and high doses intervention 5: Olodaterol comparison of low, medium low, medium high and high doses

Protocol document: